1106 10 20655 http://socictopen.socict.org/files/original/32be365c1660cebbbf190f835d4a7fcf.pdf 8a8c44fb0c8d3a4bf82d6df0dc1d7f0f Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource A comprehensive review of imaging findings in COVID-19 - status in early 2021. Creator An entity primarily responsible for making the resource Ali Afshar-Oromieh, Helmut Prosch, Cornelia Schaefer-Prokop, Karl Peter Bohn, Ian Alberts, Clemens Mingels, Majda Thurnher, Paul Cumming, Kuangyu Shi, Alan Peters, Silvana Geleff, Xiaoli Lan, Feng Wang, Adrian Huber, Christoph Gräni, Johannes T Heverhagen, Axel Rominger, Matthias Fontanellaz, Heiko Schöder, Andreas Christe, Stavroula Mougiakakou, Lukas Ebner Description An account of the resource Medical imaging methods are assuming a greater role in the workup of patients with COVID-19, mainly in relation to the primary manifestation of pulmonary disease and the tissue distribution of the angiotensin-converting-enzyme 2 (ACE 2) receptor. However, the field is so new that no consensus view has emerged guiding clinical decisions to employ imaging procedures such as radiography, computer tomography (CT), positron emission tomography (PET), and magnetic resonance imaging, and in what measure the risk of exposure of staff to possible infection could be justified by the knowledge gained. The insensitivity of current RT-PCR methods for positive diagnosis is part of the rationale for resorting to imaging procedures. While CT is more sensitive than genetic testing in hospitalized patients, positive findings of ground glass opacities depend on the disease stage. There is sparse reporting on PET/CT with [18F]-FDG in COVID-19, but available results are congruent with the earlier literature on viral pneumonias. There is a high incidence of cerebral findings in COVID-19, and likewise evidence of gastrointestinal involvement. Artificial intelligence, notably machine learning is emerging as an effective method for diagnostic image analysis, with performance in the discriminative diagnosis of diagnosis of COVID-19 pneumonia comparable to that of human practitioners. Date A point or period of time associated with an event in the lifecycle of the resource 2021 Subject The topic of the resource coronavirus, covid-19, SARS-CoV-2, imaging Identifier An unambiguous reference to the resource within a given context 10.1007/s00259-021-05375-3 Source A related resource from which the described resource is derived European journal of nuclear medicine and molecular imaging http://socictopen.socict.org/files/original/df4ac3656e162242c89c919868f9b23f.pdf d7495f96869906ad02d46b0526bfb22d Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Comprehensive evaluation of eight commercial SARS-CoV-2 IgG assays. Creator An entity primarily responsible for making the resource Mario Hönemann, Christian Lück, Melanie Maier, Corinna Pietsch, Nadine Dietze, Tom Berthold, Marco Vinicio Narvaez Encalada, Thomas Grünewald, Volker Neumeister, Alexander Dalpke, Uwe Gerd Liebert Description An account of the resource Sensitivity and specificity of serological assays are key parameters for the accurate estimation of SARS-CoV-2 sero-prevalence. The aim of this study was to compare 8 readily available IgG antibody tests using a panel of well-defined serum samples of prepandemic and pandemic origin. A cross-reaction panel included samples of patients with recent infection with either of the endemic Coronaviruses 229E, NL63, HKU1, or OC43. Additionally, samples with high antibody levels against influenza virus, adenovirus, and during acute EBV infection were included. Previous infection with endemic coronaviruses caused a significant amount of cross-reactivity in two of the assays. In contrast, the confidence intervals for the assays of Abbott, DiaSorin, Euroimmun and Roche encompassed the value of 98% for samples with a previous endemic HCoV infection. For all assays, sensitivities were between 91.3% and 98.8%. Assay performance was independent of the usage of either nucleocapsid or spike proteins. Date A point or period of time associated with an event in the lifecycle of the resource 2021 Subject The topic of the resource serology, covid-19, sensitivity, SARS-CoV-2, cross reactivity Identifier An unambiguous reference to the resource within a given context 10.1016/j.diagmicrobio.2021.115382 Source A related resource from which the described resource is derived Diagnostic microbiology and infectious disease http://socictopen.socict.org/files/original/0fb1e8a004242bf83a1c7e5cc3267b91.pdf b166f8720818eda315b99084c970c822 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Impact of the COVID-19 pandemic on tuberculosis management in Spain. Creator An entity primarily responsible for making the resource M L Aznar, J Espinosa-Pereiro, N Saborit, N Jové, F Sánchez Martinez, S Pérez-Recio, A Vitoria, S Sanjoaquin, E Gallardo, J Llenas-García, V Pomar, I O García, J Cacho, Lisbeth Goncalves De Freitas, J V San Martin, J F García Rodriguez, M Á Jiménez-Fuentes, M L De Souza-Galvao, T Tórtola, R Zules, I Molina, Adrián Sánchez-Montalvá Description An account of the resource The impact of COVID-19 on the diagnosis and management of tuberculosis (TB) patients remains unknown. Participant centres completed a structured web-based survey regarding changes in the management of TB patients during the COVID-19 pandemic. In addition, investigators included all patients ≥ 18 years with a TB diagnosis in two different periods: from March 15th to June 30th of 2020 and March 15th to June 30th, 2019. Clinical variables and information about household contacts were retrospectively collected. Seven (70%) TB Units reported changes in the TB team usual operation. A total of 169 patients were diagnosed with active TB in both periods of study (90 in 2019 and 79 in 2020). Patients diagnosed in 2020 showed more frequently bilateral lesions in CXR compared with patients diagnosed in 2019 (p = 0·004). A higher percentage of LTBI and active TB among children household contacts of patients diagnosed in 2020 compared to patients diagnosed in 2019 (p = 0·001) was observed. COVID-19 pandemic has caused substantial changes in TB care. TB patients diagnosed during COVID pandemic showed more extended pulmonary forms. The increase in LTBI infection and active TB in household children could reflect an expanded household transmission derived from antiCOVID19 measures. Date A point or period of time associated with an event in the lifecycle of the resource 2021 Subject The topic of the resource transmission, covid-19, Tuberculosis, Pandemic, impact, household contact screening Identifier An unambiguous reference to the resource within a given context 10.1016/j.ijid.2021.04.075 Source A related resource from which the described resource is derived International Journal of Infectious Diseases Publisher An entity responsible for making the resource available Elsevier http://socictopen.socict.org/files/original/bb206fc5cd301851374365cb01d14ca3.pdf 686cfddaa0a40f6543b9f2e6a75bd606 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Evidence of SARS-CoV-2 reinfection within the same clade in Ecuador: A case study. Creator An entity primarily responsible for making the resource Gabriela Sevillano, David Ortega-Paredes, Karen Loaiza, Camilo Zurita-Salinas, Jeannete Zurita Description An account of the resource To date, reported SARS-CoV-2 reinfection cases are mainly from strains belonging to different clades. As the pandemic advances, a few lineages have become dominant in certain areas leading to reinfections by similar strains. Here, we report a reinfection case within the same clade of the initial infection in a symptomatic 28-year-old-male in Quito-Ecuador. Infection was detected by reverse transcription-polymerase chain reaction, and immune response evaluated by antibody testing. Whole-genome sequencing was performed and phylogenetic analysis conducted to determine relatedness. Both the infection and the reinfection strains were assigned as Nextstrain 20B, Pangolin lineage B.1.1 and GISAID clade O. Our analysis indicated 4-6 fold more nucleotide changes than are expected for reactivation or persistence compared with the natural rate of SARS-CoV-2 mutation (∼2-3 nucleotide changes per month), thus supporting reinfection. Furthermore, approximately 3 months after the second infection, COVID-19 antibodies were not detectable in the patient, suggesting potential vulnerability to a third infection. Our results showed evidence of SARS-CoV-2 reinfection within the same clade in Ecuador, indicating that previous exposure to SARS-CoV-2 does not guarantee immunity in all cases. Date A point or period of time associated with an event in the lifecycle of the resource 2021 Subject The topic of the resource covid-19, SARS-CoV-2, Reinfection, Ecuador Identifier An unambiguous reference to the resource within a given context 10.1016/j.ijid.2021.04.073 Source A related resource from which the described resource is derived International Journal of Infectious Diseases Publisher An entity responsible for making the resource available Elsevier http://socictopen.socict.org/files/original/95346de7c3e05eae9f67e0d1e4005612.pdf 57335c504aa2805dac1301b25f78d3c6 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Comparative diagnostic performance of rapid antigen detection tests for COVID-19 in a hospital setting. Creator An entity primarily responsible for making the resource Bianca Bruzzone, Vanessa De Pace, Patrizia Caligiuri, Valentina Ricucci, Giulia Guarona, Beatrice M. Pennati, Simona Boccotti, Andrea Orsi, Giorgio Da Rin, Giancarlo Icardi, Alexander Domnich Description An account of the resource The availability of accurate and rapid diagnostic tools for COVID-19 is essential for tackling the ongoing pandemic. Our study aimed to quantify the performance of available antigen-detecting rapid diagnostic tests (Ag-RDTs) in a real-world hospital setting. In this retrospective analysis, the diagnostic performance of 7 Ag-RDTs was compared with real-time reverse transcription quantitative polymerase chain reaction assay in terms of sensitivity, specificity and expected predictive values. A total of 321 matched Ag-RDTreal-time reverse transcription quantitative polymerase chain reaction samples were analyzed retrospectively. The overall sensitivity and specificity of the Ag-RDTs was 78.7% and 100%, respectively. However, a wide range of sensitivity estimates by brand (66.0%-93.8%) and cycle threshold (Ct) cut-off values (Ct <25: 96.2%; Ct 30-35: 31.1%) was observed. The optimal Ct cut-off value that maximized sensitivity was 29. The routine use of Ag-RDTs may be convenient in moderate-to-high intensity settings when high volumes of specimens are tested every day. However, the diagnostic performance of the commercially available tests may differ substantially. Date A point or period of time associated with an event in the lifecycle of the resource 2021 Subject The topic of the resource covid-19, Italy, SARS-CoV-2, Rapid Antigen Detection Test Identifier An unambiguous reference to the resource within a given context 10.1016/j.ijid.2021.04.072 Source A related resource from which the described resource is derived International Journal of Infectious Diseases Publisher An entity responsible for making the resource available Elsevier http://socictopen.socict.org/files/original/e990f6e5ec302fc453074d13c9299ab5.pdf 6bf3cb39dbc110ce92bf2ed1476d37ad Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy. Creator An entity primarily responsible for making the resource Brad H Rovin, T Alp Ikizler, P Toby Coates, Pierre Ronco Description An account of the resource In this issue of Kidney International, the initial experience regarding the immunogenicity of prior coronavirus disease 2019 (COVID-19) infection and the response to the COVID-19 vaccines among patients on maintenance dialysis and kidney transplant recipients is summarized. Preliminary data suggest that there is durability of immune response after COVID-19 infection. Although immune response to the first dose of vaccine is less in infection-naïve patients than healthy individuals in both groups, after the second vaccine dose a significant portion of patients receiving maintenance dialysis develop robust antibody titers, whereas kidney transplant recipients show a less-strong immune response. Date A point or period of time associated with an event in the lifecycle of the resource 2021 Identifier An unambiguous reference to the resource within a given context 10.1016/j.kint.2021.04.007 Source A related resource from which the described resource is derived Kidney international http://socictopen.socict.org/files/original/36be1e86b41fbec4a8e1bbb1e7ecece8.pdf 98485615f25449f9858e51fbc391e796 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Diagnostic accuracy of three SARS-CoV2 antibody detection assays, neutralizing effect and longevity of serum antibodies. Creator An entity primarily responsible for making the resource Marina Bubonja-Šonje, Lara Batičić, Maja Abram, Đurđica Cekinović Grbeša Description An account of the resource Evidence is currently insufficient to know whether SARS-CoV-2 antibodies (Abs) protect from future infection and how long immunity will last. The kinetics of the immune response to SARS-CoV-2 infection and role of serology in estimating individual protective immunity is yet to be established. We evaluated diagnostic performances of three serological assays - Abbott Architect CMIA IgG, bioMerieux VIDAS ELFA IgG/IgM, and Diesse Chorus ELISA IgG/IgM, and analyzed longevity and potential neutralizing effect of SARS-CoV-2 Abs in COVID-19 patients. Clinical sensitivities of assessed IgG tests two to three weeks post symptom onset (PSO) were very high: 96.77 % for Architect, 96.77 % for Chorus, and 100.00 % for VIDAS. Sensitivities of two assessed IgM assays were moderate: 74.07 % for Chorus, and 76.92 % for VIDAS. Specificities were excellent for all assessed IgG assays: 99.01 % for Architect and 100 % for Chorus and VIDAS. Chorus and VIDAS IgM assays also achieved excellent specificity of 99.01 % and 100 %, respectively. In most cases IgG Abs were still present eight months PSO. Neutralizing antibodies were detected in majority of serum samples from convalescent patients. Serum samples from severe COVID-19 patients had higher antibody titers and higher neutralizing activity. We observed a strong positive correlation among SARS-CoV-2 IgG antibody titer and neutralizing activity. The strongest positive correlation to neutralizing activity was found for VIDAS IgG assay. Date A point or period of time associated with an event in the lifecycle of the resource 2021 Subject The topic of the resource covid-19, Antibody testing, serological testing, SARS-CoV-2 neutralizing activity Identifier An unambiguous reference to the resource within a given context 10.1016/j.jviromet.2021.114173 Source A related resource from which the described resource is derived Journal of virological methods http://socictopen.socict.org/files/original/7c5fb3664170111db7f983b4d5465c7f.pdf 7ce19f81df07f089d34356ba5ac65bf8 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource COVID19 outbreak in Lombardy, Italy: An analysis on the short-term relationship between air pollution, climatic factors and the susceptibility to SARS-CoV-2 infection. Creator An entity primarily responsible for making the resource Angela Stufano, Stefania Lisco, Nicola Bartolomeo, Antonella Marsico, Guglielmo Lucchese, Hamidreza Jahantigh, Leonardo Soleo, Massimo Moretti, Paolo Trerotoli, Giuseppe De Palma, Piero Lovreglio Description An account of the resource Short-term exposure to air pollution, as well as to climate variables have been linked to a higher incidence of respiratory viral diseases. The study aims to assess the short-term influence of air pollution and climate on COVID19 incidence in Lombardy (Italy), during the early stage of the outbreak, before the implementation of the lockdown measures. The daily number of COVID19 cases in Lombardy from February 25th to March 10th, 2020, and the daily average concentrations up to 15 days before the study period of particulate matter (PM10, PM2.5), O3, SO2, and NO2 together with climate variables (temperature, relative humidity - RH%, wind speed, precipitation), were analyzed. A univariable mixed model with a logarithm transformation as link function was applied for each day, from 15 days (lag15) to one day (lag1) before the day of detected cases, to evaluate the effect of each variable. Additionally, change points (Break Points-BP) in the relationship between incident cases and air pollution or climatic factors were estimated. The results did not show a univocal relationship between air quality or climate factors and COVID19 incidence. PM10, PM2.5 and O3 concentrations in the last lags seem to be related to an increased COVID19 incidence, probably due to an increased susceptibility of the host. In addition, low temperature and low wind speed in some lags resulted associated with increased daily COVID19 incidence. The findings observed suggest that these factors, in particular conditions and lags, may increase individual susceptibility to the development of viral infections such as SARS-CoV-2. Date A point or period of time associated with an event in the lifecycle of the resource 2021 Subject The topic of the resource covid-19, SARS-CoV-2, air pollution, climate, Respiratory virus infection Identifier An unambiguous reference to the resource within a given context 10.1016/j.envres.2021.111197 Source A related resource from which the described resource is derived Environmental research http://socictopen.socict.org/files/original/657791dd5182246de7a152f174d2c688.pdf 6a44cc560aa8f8d6214fa83dee85dfed Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Creator An entity primarily responsible for making the resource Adam G Laing, Leticia Monin, Miguel Muñoz-Ruiz, Duncan R McKenzie, Thomas S Hayday, Shraddha Kamdar, Magdalene Joseph, Richard Davis, Sultan Abdul-Jawad, Jeffrey Seow, Katie J Doores, Jennifer Vidler, Michael H Malim, Irene Del Molino Del Barrio, Thanussuyah Alaguthurai, Clara Domingo-Vila, Carl Graham, Elizabeth Harvey-Jones, Rosalind Graham, Jack Cooper, Muhammad Khan, Helen Kakkassery, Shubhankar Sinha, Liane Dupont, Isaac Francos Quijorna, Charlotte O'Brien-Gore, Puay Ling Lee, Josephine Eum, Maria Conde Poole, Daniel Davies, Yin Wu, Angela Swampillai, Bernard V North, Ana Montes, Mark Harries, Anne Rigg, James Spicer, Paul Fields, Piers Patten, Francesca Di Rosa, Sophie Papa, Timothy Tree, Adrian C Hayday, Sheeba Irshad Description An account of the resource The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients with cancer is unknown. We aimed to assess the safety and immunogenicity of the BNT162b2 (Pfizer-BioNTech) vaccine in patients with cancer. For this prospective observational study, we recruited patients with cancer and healthy controls (mostly health-care workers) from three London hospitals between Dec 8, 2020, and Feb 18, 2021. Participants who were vaccinated between Dec 8 and Dec 29, 2020, received two 30 μg doses of BNT162b2 administered intramuscularly 21 days apart; patients vaccinated after this date received only one 30 μg dose with a planned follow-up boost at 12 weeks. Blood samples were taken before vaccination and at 3 weeks and 5 weeks after the first vaccination. Where possible, serial nasopharyngeal real-time RT-PCR (rRT-PCR) swab tests were done every 10 days or in cases of symptomatic COVID-19. The coprimary endpoints were seroconversion to SARS-CoV-2 spike (S) protein in patients with cancer following the first vaccination with the BNT162b2 vaccine and the effect of vaccine boosting after 21 days on seroconversion. All participants with available data were included in the safety and immunogenicity analyses. Ongoing follow-up is underway for further blood sampling after the delayed (12-week) vaccine boost. This study is registered with the NHS Health Research Authority and Health and Care Research Wales (REC ID 20/HRA/2031). 151 patients with cancer (95 patients with solid cancer and 56 patients with haematological cancer) and 54 healthy controls were enrolled. For this interim data analysis of the safety and immunogenicity of vaccinated patients with cancer, samples and data obtained up to March 19, 2021, were analysed. After exclusion of 17 patients who had been exposed to SARS-CoV-2 (detected by either antibody seroconversion or a positive rRT-PCR COVID-19 swab test) from the immunogenicity analysis, the proportion of positive anti-S IgG titres at approximately 21 days following a single vaccine inoculum across the three cohorts were 32 (94%; 95% CI 81-98) of 34 healthy controls; 21 (38%; 26-51) of 56 patients with solid cancer, and eight (18%; 10-32) of 44 patients with haematological cancer. 16 healthy controls, 25 patients with solid cancer, and six patients with haematological cancer received a second dose on day 21. Of the patients with available blood samples 2 weeks following a 21-day vaccine boost, and excluding 17 participants with evidence of previous natural SARS-CoV-2 exposure, 18 (95%; 95% CI 75-99) of 19 patients with solid cancer, 12 (100%; 76-100) of 12 healthy controls, and three (60%; 23-88) of five patients with haematological cancers were seropositive, compared with ten (30%; 17-47) of 33, 18 (86%; 65-95) of 21, and four (11%; 4-25) of 36, respectively, who did not receive a boost. The vaccine was well tolerated; no toxicities were reported in 75 (54%) of 140 patients with cancer following the first dose of BNT162b2, and in 22 (71%) of 31 patients with cancer following the second dose. Similarly, no toxicities were reported in 15 (38%) of 40 healthy controls after the first dose and in five (31%) of 16 after the second dose. Injection-site pain within 7 days following the first dose was the most commonly reported local reaction (23 [35%] of 65 patients with cancer; 12 [48%] of 25 healthy controls). No vaccine-related deaths were reported. In patients with cancer, one dose of the BNT162b2 vaccine yields poor efficacy. Immunogenicity increased significantly in patients with solid cancer within 2 weeks of a vaccine boost at day 21 after the first dose. These data support prioritisation of patients with cancer for an early (day 21) second dose of the BNT162b2 vaccine. King's College London, Cancer Research UK, Wellcome Trust, Rosetrees Trust, and Francis Crick Institute. Date A point or period of time associated with an event in the lifecycle of the resource 2021 Identifier An unambiguous reference to the resource within a given context 10.1016/S1470-2045(21)00213-8 Source A related resource from which the described resource is derived The Lancet. Oncology http://socictopen.socict.org/files/original/8265608d09a2b0cd42eecbdd69aaa839.pdf d663d7e17d82d4abf1686953ecc912df Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Creator An entity primarily responsible for making the resource Sebastien Ourselin, Mark S Graham, Liane S Canas, Benjamin Murray, Marc Modat, Jonathan Wolf, Kerstin Klaser, Michela Antonelli, Anna May, Lorenzo Polidori, Somesh Selvachandran, Christina Hu, Joan Capdevila, Cristina Menni, Panayiotis Louca, Carole H Sudre, Long H Nguyen, David A Drew, Jordi Merino, Erika Molteni, Amit D Joshi, Massimo Mangino, Alexander Hammers, Anna L Goodman, Andrew T Chan, Claire J Steves, Ana M Valdes, Tim D Spector Description An account of the resource The Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca (ChAdOx1 nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase 3 trials. We aimed to investigate the safety and effectiveness of these vaccines in a UK community setting. In this prospective observational study, we examined the proportion and probability of self-reported systemic and local side-effects within 8 days of vaccination in individuals using the COVID Symptom Study app who received one or two doses of the BNT162b2 vaccine or one dose of the ChAdOx1 nCoV-19 vaccine. We also compared infection rates in a subset of vaccinated individuals subsequently tested for SARS-CoV-2 with PCR or lateral flow tests with infection rates in unvaccinated controls. All analyses were adjusted by age (≤55 years vs >55 years), sex, health-care worker status (binary variable), obesity (BMI <30 kg/m2vs ≥30 kg/m2), and comorbidities (binary variable, with or without comorbidities). Between Dec 8, and March 10, 2021, 627 383 individuals reported being vaccinated with 655 590 doses: 282 103 received one dose of BNT162b2, of whom 28 207 received a second dose, and 345 280 received one dose of ChAdOx1 nCoV-19. Systemic side-effects were reported by 13·5% (38 155 of 282 103) of individuals after the first dose of BNT162b2, by 22·0% (6216 of 28 207) after the second dose of BNT162b2, and by 33·7% (116 473 of 345 280) after the first dose of ChAdOx1 nCoV-19. Local side-effects were reported by 71·9% (150 023 of 208 767) of individuals after the first dose of BNT162b2, by 68·5% (9025 of 13 179) after the second dose of BNT162b2, and by 58·7% (104 282 of 177 655) after the first dose of ChAdOx1 nCoV-19. Systemic side-effects were more common (1·6 times after the first dose of ChAdOx1 nCoV-19 and 2·9 times after the first dose of BNT162b2) among individuals with previous SARS-CoV-2 infection than among those without known past infection. Local effects were similarly higher in individuals previously infected than in those without known past infection (1·4 times after the first dose of ChAdOx1 nCoV-19 and 1·2 times after the first dose of BNT162b2). 3106 of 103 622 vaccinated individuals and 50 340 of 464 356 unvaccinated controls tested positive for SARS-CoV-2 infection. Significant reductions in infection risk were seen starting at 12 days after the first dose, reaching 60% (95% CI 49-68) for ChAdOx1 nCoV-19 and 69% (66-72) for BNT162b2 at 21-44 days and 72% (63-79) for BNT162b2 after 45-59 days. Systemic and local side-effects after BNT162b2 and ChAdOx1 nCoV-19 vaccination occur at frequencies lower than reported in phase 3 trials. Both vaccines decrease the risk of SARS-CoV-2 infection after 12 days. ZOE Global, National Institute for Health Research, Chronic Disease Research Foundation, National Institutes of Health, UK Medical Research Council, Wellcome Trust, UK Research and Innovation, American Gastroenterological Association. Date A point or period of time associated with an event in the lifecycle of the resource 2021 Identifier An unambiguous reference to the resource within a given context 10.1016/S1473-3099(21)00224-3 Source A related resource from which the described resource is derived The Lancet. Infectious diseases